HOME VII共识:特应性皮炎试验核心结局工具推荐
HOME VII共识会议于2019年4月在日本东京召开,75名参与者来自16个国家,通过证据展示、小组讨论和匿名投票达成共识。会议推荐生活质量用DLQI(成人)、CDLQI(儿童)和IDQoL(婴儿)测量,长期控制用RECAP或ADCT,瘙痒强度用峰值瘙痒NRS-11(过去24小时)作为附加工具。所有核心结局工具至少应在基线和主要结局评估时采集。
要点
- 生活质量核心工具:成人用DLQI,儿童用CDLQI,婴儿用IDQoL。
- 长期控制核心工具:RECAP或ADCT,但数据采集频率未达成共识。
- 瘙痒强度:峰值瘙痒NRS-11(过去24小时)作为症状域附加工具,用于年长儿童和成人试验。
核心结论
- 特应性皮炎临床试验的核心结局集现已完整,新试验和系统评价应使用指定的域和工具。
研究设计与样本
- 面对面共识会议(2019年4月8-10日,日本东京),75名参与者(49名医疗专业人员/方法学家、14名患者、12名行业代表)来自16个国家,采用预设共识规则进行匿名投票。
主要发现
- 共识同意生活质量用DLQI(成人)、CDLQI(儿童)、IDQoL(婴儿)测量。
- 长期控制用RECAP或ADCT测量,但数据采集频率未达成共识。
- 峰值瘙痒NRS-11(过去24小时)被推荐为年长儿童和成人试验中症状域的附加工具。
- 同意所有核心结局工具至少应在基线和主要结局评估时采集。
关键数值与推荐
- 生活质量:成人用DLQI,儿童用CDLQI,婴儿用IDQoL。
- 长期控制:RECAP或ADCT。
- 瘙痒强度:峰值瘙痒NRS-11(过去24小时)作为附加工具用于年长儿童和成人。
- 数据采集最低时间点:基线和主要结局评估时。
临床怎么用
- 在所有新特应性皮炎临床试验和湿疹治疗系统评价中,应采用本共识指定的核心域和工具。
局限性
- 长期控制的数据采集频率未达成共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema (AE) clinical trials. Previous consensus meetings have agreed on preferred instruments for clinician-reported signs (Eczema Area and Severity Index, EASI) and patient-reported symptoms (Patient-Oriented Eczema Measure, POEM). This paper reports consensus decisions from the HOME VII meeting. OBJECTIVES: To complete the core outcome set for AE by agreeing on core outcome instruments for the domains of quality of life (QoL), long-term control and itch intensity. METHODS: A face-to-face consensus meeting was held in Tokyo, Japan (8-10 April 2019) including 75 participants (49 healthcare professionals/methodologists, 14 patients, 12 industry representatives) from 16 countries. Consensus decisions were made by presentations of evidence, followed by whole and small group discussions and anonymous voting using predefined consensus rules. RESULTS: It was agreed by consensus that QoL should be measured using the Dermatology Life Quality Index (DLQI) for adults, the Children's Dermatology Life Quality Index (CDLQI) for children and the Infant's Dermatology Quality of Life Index (IDQoL) for infants. For long-term control, the Recap of Atopic Eczema (RECAP) instrument or the Atopic Dermatitis Control Test (ADCT) should be used. Consensus was not reached over the frequency of data collection for long-term control. The peak itch numerical rating scale (NRS)-11 past 24 h was recommended as an additional instrument for the symptom domain in trials of older children and adults. Agreement was reached that all core outcome instruments should be captured at baseline and at the time of primary outcome assessment as a minimum. CONCLUSIONS: For now, the core outcome set for clinical trials in AE is complete. The specified domains and instruments should be used in all new clinical trials and systematic reviews of eczema treatments.
引用
- Thomas KS, Apfelbacher CA, Chalmers JR, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Br J Dermatol. 2021. PMID: 33393074. doi:10.1111/bjd.19751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。